Application of CXCL1 in diagnosis of calcified aortic valve disease

By detecting the expression level of CXCL1, a diagnostic model was constructed using a reagent kit and machine learning algorithms, which solved the problems of convenience and effectiveness in the diagnosis of calcific aortic valve disease, and achieved early diagnosis with high accuracy and sensitivity.

CN121577893APending Publication Date: 2026-02-27FUWAI HOSPITAL CHINESE ACAD OF MEDICAL SCI & PEKING UNION MEDICAL COLLEGE
0 Cites 0 Cited by

Patent Information

Application Number
CN202511652349.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-11-12
Publication Date
2026-02-27

AI Technical Summary

Technical Problem

Current technologies lack convenient and effective methods for diagnosing calcific aortic valve disease. Existing diagnostic methods, such as physical examination, have low sensitivity, echocardiogram image quality is affected by the patient's body size, and cardiac CT carries radiation risks. Finding a more convenient and effective diagnostic method is an urgent technical problem to be solved.

Method used

Using CXCL1 as a biomarker, the expression level of CXCL1 in samples is detected, and diagnostic methods are employed using reagent kits, chips, test strips, and other products. A diagnostic model is constructed by combining machine learning algorithms to achieve early diagnosis of calcific aortic valve disease.

Benefits of technology

CXCL1 demonstrates good diagnostic efficacy, with high accuracy and sensitivity, providing a new approach to the diagnosis of CAVD and possessing significant scientific and clinical application value.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention discloses an application of CXCL1 in diagnosis of a calcified aortic valve disease. According to the invention, it is found for the first time that CXCL1 can be used in early diagnosis of calcified aortic valve disease (CAVD), and it is found through verification of a real clinical sample collected by the invention that CXCL1 has good diagnosis efficiency on diagnosis of CAVD, and the accuracy, sensitivity and specificity are all high. The invention provides a new thought and strategy for the technical field of CAVD diagnosis, and has important scientific significance and clinical application value.
Need to check novelty before this filing date? Find Prior Art